MA40894A - HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES - Google Patents

HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES

Info

Publication number
MA40894A
MA40894A MA040894A MA40894A MA40894A MA 40894 A MA40894 A MA 40894A MA 040894 A MA040894 A MA 040894A MA 40894 A MA40894 A MA 40894A MA 40894 A MA40894 A MA 40894A
Authority
MA
Morocco
Prior art keywords
lymphocytes
target
production processes
heterodimeric immunoglobulins
heterodimeric
Prior art date
Application number
MA040894A
Other languages
French (fr)
Inventor
Jonathan Back
Samuel Hou
Rami Lissilaa
Romain Ollier
Darko Skegro
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MA40894A publication Critical patent/MA40894A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA040894A 2014-11-04 2015-11-02 HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES MA40894A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2014/073738 WO2015063339A1 (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins
EP15167034 2015-05-08

Publications (1)

Publication Number Publication Date
MA40894A true MA40894A (en) 2017-09-12

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040894A MA40894A (en) 2014-11-04 2015-11-02 HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES

Country Status (20)

Country Link
EP (1) EP3215541A1 (en)
JP (3) JP2018501297A (en)
KR (1) KR102760422B1 (en)
CN (1) CN107207596A (en)
AU (1) AU2015341884B2 (en)
BR (1) BR112017009263A2 (en)
CA (1) CA2965745C (en)
CL (1) CL2017001090A1 (en)
CO (1) CO2017005240A2 (en)
EA (1) EA039658B1 (en)
HK (1) HK1244014A1 (en)
IL (1) IL251848A0 (en)
MA (1) MA40894A (en)
MX (1) MX2017005814A (en)
MY (1) MY186929A (en)
NZ (1) NZ732019A (en)
PE (1) PE20171041A1 (en)
PH (1) PH12017500819A1 (en)
SG (1) SG11201703313SA (en)
WO (1) WO2016071355A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CN105051069B (en) 2013-01-14 2019-12-10 Xencor股份有限公司 Novel heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
DK3406633T3 (en) 2013-07-25 2022-03-28 Cytomx Therapeutics Inc MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVABLE ANTIBODIES AND METHODS OF USING IT
EP3066133A1 (en) 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins
KR102497443B1 (en) 2014-03-28 2023-02-08 젠코어 인코포레이티드 Bispecific antibodies that bind to cd38 and cd3
AU2015292406B2 (en) * 2014-07-25 2021-03-11 Cytomx Therapeutics, Inc Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
BR112017011166A2 (en) 2014-11-26 2018-02-27 Xencor, Inc. heterodimeric antibodies that bind to cd3 and cd38
CA2967426A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
EA039859B1 (en) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
CN108699136B (en) 2015-12-07 2022-03-18 Xencor股份有限公司 Heterodimeric antibodies that bind CD3 and PSMA
TN2018000266A1 (en) 2016-02-03 2020-01-16 Amgen Res Munich Gmbh Psma and cd3 bispecific t cell engaging antibody constructs.
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
MX2018016265A (en) 2016-06-28 2019-07-04 Xencor Inc Heterodimeric antibodies that bind somatostatin receptor 2.
WO2018197502A1 (en) * 2017-04-24 2018-11-01 Glenmark Pharmaceuticals S.A. T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3634998B8 (en) * 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
EP3635002A1 (en) * 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
EP3635001A1 (en) 2017-06-08 2020-04-15 Black Belt Therapeutics Limited Cd38 modulating antibody
ES2911243T3 (en) * 2017-08-10 2022-05-18 Grifols Diagnostic Solutions Inc Compositions, methods and/or kits comprising a recombinant extracellular domain of human cd38
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
KR102770107B1 (en) 2017-08-16 2025-02-20 블랙 벨트 테라퓨틱스 리미티드 CD38 regulatory antibody
KR102770110B1 (en) 2017-08-16 2025-02-20 블랙 벨트 테라퓨틱스 리미티드 CD38 antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
AU2018347607B2 (en) 2017-10-14 2025-08-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR20200085828A (en) 2017-11-08 2020-07-15 젠코어 인코포레이티드 Bispecific and monospecific antibodies using novel anti-PD-1 sequences
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
AU2019348606A1 (en) * 2018-09-25 2021-04-15 Ichnos Sciences S.A. Antibody quantification in biological samples
KR102353568B1 (en) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability
SG11202107941TA (en) * 2019-01-23 2021-08-30 Encefa Cd31 competitors and uses thereof
WO2020182984A2 (en) * 2019-03-13 2020-09-17 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
CA3139111A1 (en) * 2019-05-23 2020-11-26 VelosBio Inc. Anti-ror1/anti-cd3 bispecific binding molecules
WO2020250940A1 (en) * 2019-06-11 2020-12-17 小野薬品工業株式会社 Immunosuppression agent
CN110551222B (en) * 2019-08-27 2023-06-06 重庆市畜牧科学院 A novel bifunctional antibody and its application
CN112538114B (en) * 2019-09-20 2025-05-02 上海普铭生物科技有限公司 Anti-human CD38 antibody and its application
TWI841790B (en) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 Antibodies targeting CD3, bispecific antibodies and their uses
CN115362346A (en) 2020-03-19 2022-11-18 深圳纽迪瑞科技开发有限公司 Strain sensing membrane, pressure sensor and hybrid strain sensing system
CN113493519B (en) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases
WO2021216972A1 (en) * 2020-04-24 2021-10-28 Memorial Sloan Kettering Cancer Center Anti-cd3 antibodies and uses thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4168450A2 (en) * 2020-06-17 2023-04-26 Y-Mabs Therapeutics, Inc. Cd38 antibodies for the treatment of human diseases
JP7773528B2 (en) 2020-08-19 2025-11-19 ゼンコア インコーポレイテッド Anti-CD28 composition
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (en) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Heterodimeric antibodies binding to CD3 and GPC3
US20250340637A1 (en) * 2021-08-04 2025-11-06 Abpro Corporation Cd3 targeting antibodies and uses thereof
CN118108852B (en) * 2023-11-23 2025-11-18 浙江大学 A monoclonal antibody against acetamiprid and its recombinant full-length IgG expression plasmid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548990A (en) * 2004-02-06 2009-06-26 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
KR20150139636A (en) * 2005-10-12 2015-12-11 모르포시스 아게 Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR101747103B1 (en) * 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 Readily isolated bispecific antibodies with native immunoglobulin format
RU2606264C2 (en) * 2009-12-25 2017-01-10 Чугаи Сеияку Кабушики Каиша Method of modification of polypeptide for purification of polypeptide multimers
EP3613774A1 (en) * 2010-06-09 2020-02-26 Genmab A/S Antibodies against human cd38
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
US9683052B2 (en) * 2011-03-25 2017-06-20 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP2914302B1 (en) * 2012-11-05 2017-01-04 MorphoSys AG Radiolabelled antibody and uses thereof
EP3066133A1 (en) * 2013-11-04 2016-09-14 Glenmark Pharmaceuticals S.A. Production of t cell retargeting hetero-dimeric immunoglobulins

Also Published As

Publication number Publication date
CA2965745C (en) 2023-12-05
EP3215541A1 (en) 2017-09-13
AU2015341884A1 (en) 2017-06-08
NZ732019A (en) 2022-07-29
KR102760422B1 (en) 2025-02-03
WO2016071355A1 (en) 2016-05-12
CL2017001090A1 (en) 2018-01-05
BR112017009263A2 (en) 2018-01-30
JP2019214582A (en) 2019-12-19
IL251848A0 (en) 2017-06-29
CA2965745A1 (en) 2016-05-12
JP2021184722A (en) 2021-12-09
AU2015341884B2 (en) 2020-09-17
HK1244014A1 (en) 2018-07-27
PH12017500819A1 (en) 2017-10-02
JP2018501297A (en) 2018-01-18
CN107207596A (en) 2017-09-26
EA039658B1 (en) 2022-02-22
PE20171041A1 (en) 2017-07-19
SG11201703313SA (en) 2017-05-30
MX2017005814A (en) 2017-08-02
JP7403505B2 (en) 2023-12-22
KR20170078831A (en) 2017-07-07
MY186929A (en) 2021-08-26
CO2017005240A2 (en) 2017-10-31
EA201790961A1 (en) 2017-10-31

Similar Documents

Publication Publication Date Title
MA40894A (en) HETERODIMERIC IMMUNOGLOBULINS RE-TARGET CD3 / CD38 T-LYMPHOCYTES AND THEIR PRODUCTION PROCESSES
HUS2500002I1 (en) Novel anti-pd-l1 antibodies
EP3706784A4 (en) COMPOSITIONS AND PROCESSES FOR THE PRODUCTION OF T LYMPHOCYTES
IL252467A0 (en) Heterodimeric antibodies that bind cd3 and cd38
IL255727A (en) Novel anti-pd-l1 antibodies
IL248007A0 (en) Bispecific antibodies that bind to cd38 and cd3
MA40889A (en) HEREODIMERIC IMMUNOGLOBULINS RE-TARGET LYMPHOCYTES
EP3397263A4 (en) PROCESSES FOR PRODUCING T CELLS AND LYMPHOCYTES AS PRODUCED
SG10201603721TA (en) Anti-CTLA-4 Antibodies
EP2991646A4 (en) METHODS AND COMPOSITIONS FOR INCREASING CD4 + T LYMPHOCYTES REGULATORS
SG11201705552QA (en) Anti-pd-l1 antibodies
EP3341485A4 (en) ENHANCED PRODUCTION OF IMMUNOGLOBULINS
MA41375A (en) BISPECIFIC IGG ANTIBODIES AND THEIR PREPARATION PROCESSES
EP3515503A4 (en) MANIPULATED LYMPHOCYTES
MA42829A (en) COMPOSITIONS DERIVED FROM PLACENTA AND PROCESSES FOR PRODUCING THEM
ME03417B (en) PLADIENOLIDE PYRIDINE COMPOUNDS AND PROCESSES FOR USE
FI20155385A7 (en) Methods for the continuous production of products from microorganisms
EP3368087A4 (en) COMPOSITE BIOADHESI SEALING PRODUCT
MA44517A (en) RECOMBINANT INTRAVENOUS IMMUNOGLOBULIN (RIVIG) COMPOSITIONS AND PROCESSES FOR PRODUCTION AND USE
EP3393269A4 (en) FERMENTED PLANT PROTEIN COMPOSITIONS PROCESSES FOR PRODUCING THE SAME
MA45831A (en) BED ANTI-BODY MONOCLONAL ANTIBODIES AND THEIR PRODUCTION AND USE PROCESSES
EP3340979A4 (en) COMPOSITIONS AND METHODS FOR THE SENSITIZATION OF PARASITES TO A MEDICINAL PRODUCT
EP3324983A4 (en) METHODS AND MATERIALS FOR PRODUCING T-LYMPHOCYTES
EP3365015A4 (en) COMPOSITIONS AND METHODS FOR ANTICANCER THERAPY WITH IMMUNE MEDIATION
EP3344661C0 (en) IRON-POLYSACCHARIDE COMPLEXES AND PROCESSES FOR THEIR PREPARATION